While retaining HIV-infected patients in medical care has been shown

to be associated with improved health outcomes, data from industrial [8] and developing countries [27] have shown that there are difficulties in patient retention. In our study, the rate of LTFU was 3.76 (95% CI 3.58–3.95)/100 py, which is similar to the 3.72 (95% CI 3.58–3.86)/100 py reported by the EuroSIDA study group [10]. In the SHCS, people originating from regions other than northwestern countries were at risk for LTFU, as shown in the French Hospital Database [11]. Although demographically similar to southeastern Asians, in the present study sub-Saharan Africans had a disproportionally high LTFU. In research on sub-Saharan Africans at one of the SHCS centres [4], it was found that the majority of those who had left the country had been denied asylum. An uncertain legal situation, with the risk

of deportation through MK0683 the asylum process, which has also been described in other countries, is likely to contribute to LTFU [28]. Older participants had a better retention rate, which is in accordance with other recent data [10,11,29]. Older age may be a proxy for less mobility and more comorbidity. Although a large proportion of participants with IDU as the transmission risk in Switzerland have stopped injecting drugs [30], IDU remains an important and independent risk factor for LTFU [10,11,29]. People with a higher baseline CD4 cell count or who were treatment-naïve were more prone NVP-BEZ235 supplier to LTFU, a finding in congruence with research from France [29]. However, using time-updated CD4 cell counts for multivariable analyses, it was found that participants more likely to be lost to follow-up were those with lower latest CD4 cell counts. This has been observed in other cohort studies [10,29] in which time-updated CD4 cell counts were applied. Some of these patients may have been less adherent to treatment, or they may have died without documentation in the cohort database. Immigrants

were less likely to participate in the SHCS, with people from sub-Saharan Africa having the greatest probability of nonparticipation. Participating in the SHCS implies written informed consent. Concerns about disclosure Neratinib in vivo could discourage sub-Saharan Africans from signing. Compared with other European countries with high numbers of immigrants, Switzerland has small, fractured immigrant groups that are divided by the barriers of the country’s four different language regions. If immigrants rely on a small community of fellow nationals for support, they might be more inclined to avoid disclosure, fearing to risk their social status [31]. Among sub-Saharan Africans, men were the most vulnerable group for cohort nonparticipation. This is consistent with findings from African countries showing that men access ART less frequently and at a more advanced stage of HIV infection compared with women [32,33].